New monograph: Ondexxya® [andexanet alfa] for reversal of apixaban or rivaroxaban in life-threatening or uncontrolled bleeding (specialist supervision in hospital).
New monograph: Libtayo® [cemiplimab] for cutaneous squamous cell carcinoma (specialist use only).
New monograph: Emgality® [galcanezumab] for prophylaxis of migraine [in patients who have at least 4 migraine days per month] (initiated by a specialist).
New monograph: Dovato® [lamivudine with dolutegravir] for HIV-1 infection.
New monograph: Onpattro® [patisiran] for stage 1 or stage 2 polyneuropathy in patients with hereditary transthyretin amyloidosis (hATTR) (initiated under specialist supervision).
Carfilzomib (Kyprolis®): reminder of risk of potentially fatal cardiac events [MHRA/CHM advice].
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma [NICE guidance].
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer [NICE guidance].
Dapagliflozin with insulin for treating type 1 diabetes [NICE guidance].
Daratumumab (Darzalex®): risk of reactivation of hepatitis B virus [MHRA/CHM advice].
Naltrexone with bupropion (Mysimba®): risk of adverse reactions that could affect ability to drive [MHRA/CHM advice].
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [NICE guidance].
Patisiran for treating hereditary transthyretin amyloidosis [NICE guidance].
Pentosan polysulfate sodium (Elmiron®): risk of pigmentary maculopathy [MHRA/CHM advice].
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer [NICE guidance].
Risankizumab for treating moderate to severe plaque psoriasis [NICE guidance].
Vedolizumab for treating moderately to severely active ulcerative colitis [NICE guidance].
Hyperparathyroidism: new guidance on management of primary hyperparathyroidism.
Prostate Cancer: updated guidance on management.
Dose Changes for BNF only
Vitamin B substances with ascorbic acid: Duration and route for the treatment of suspected or established Wernicke's encephalopathy, and prophylaxis of Wernicke's encephalopathy updated.